LONDON: The combination of new drugs can suppress infection by the SARS-COV-2 virus, which causes Covid-19, according to a study conducted on cell animals and culture.
The results of the initial test, published in the journal virus, found that the use of the combined drug antivirus drugs Nafamostat and Pegasys fulfilled all the requirements of availability and efficacy.
“This combination effectively suppresses infection,” said Denis Kainov, a professor at the University of Science and Technology Norway (NTNU).
Experiments were carried out in cell culture and hamsters, the researchers said.
They note that this does not always mean it’s a combination of work in humans, but it can be a hot tip for researchers who have tested the nafamostat in the war against Covid-19.
According to Nafamostat researchers have been used as monotherapy against Covid-19 and are undergoing extensive testing in Japan, among other places.
Pegasys are currently used to treat hepatitis C.
Combining both seems to have a positive effect, they say.
“Both drugs attack factors in our cell called TMPRSS2, which plays an important role in viral replication,” said Magnar Bjoras, a professor at NTNU.
The researchers noted that only a low dose of the combination drug needed.
“Low doses of drugs in combination may have some al-profit clinics.
Including fewer side effects and increased results for patients,” said Aleksandr Ianevski, a doctoral research partner at NTNU.
The researchers believe that combination medicine can save lives and make life easier for patients.
Nafamostat is relatively cheap while the downside of pegasys is a higher cost, they pay attention.
“SARS-COV-2 and the variant of the vaccine / immunity continues to cause a serious threat to public health due to lack of effective and growing treatment, and is available,” Recorded research writers.
“Our studies can provide proactive solutions for sustainable pandemics and the potential of future Coronavirus outbreaks, which are still very much needed in many parts of the world,” he added.
Apart from NTNU, another researcher in this study came from Oslo University Hospital.
, University of Oslo, both in Norway, French Precision Medical Company Oncodesign, University of Tartu in Estonia and University of Helsinki in Finland.